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Abstract: Mitogen-activated protein kinase (MAPK) phosphatase-3 (MKP-3) and its 
substrates (extracellular signal-regulated kinase [ERK] and p38) play an important role in 
pathophysiological mechanisms of acute postoperative and chronic neuropathic pain in the 
spinal cord. This study aimed to understand the role of MKP-3 and its target MAPKs at the 
site of surgical incision in nociceptive behavior. Wild-type (WT) and MKP-3 knockout (KO) 
mice underwent unilateral plantar hind paw incision. Mechanical allodynia was assessed 
by using von Frey filaments. Peripheral ERK-1/2 and p38 phosphorylation were measured 
by Western blot. Cell infiltration was determined using hematoxylin and eosin histological 
staining. Peripheral phosphorylated ERK-1/2 (p-ERK-1/2) inhibition was performed in 
MKP-3 KO mice. In WT mice, mechanical hypersensitivity was observed on postoperative 
day 1 (0.69±0.17 g baseline vs 0.13±0.08 g day 1), which resolved normally by postopera-
tive day 12 (0.46±0.08 g, N=6). In MKP-3 KO mice, this hypersensitivity persisted at least 
12 days after surgery (0.19±0.06 g; N=6). KO mice displayed higher numbers of infiltrat-
ing cells (51.4±6 cells/0.1 mm2) than WT mice (8.7±1.2 cells/0.1 mm2) on postoperative 
day 1 (vs 5–6 cells/0.1 mm2 at baseline) that returned to baseline 12 days after surgery 
(10–12 cells/0.1 mm2). In WT mice, peripheral p-p38 and p-ERK-1/2 expression increased 
(5- and 3-fold, respectively) on postoperative days 1 and 5, and returned to basal levels 
7–12 days after surgery (N=3 per group). Peripheral p-p38 levels in MKP-3 KO mice fol-
lowed a similar expression pattern as WT mice. Peripheral p-ERK-1/2 levels in MKP-3 KO 
mice remained elevated 12 days after surgery (2.5-fold, N=3 per group). Administration of 
PD98059 (MEK inhibitor, N=8, vehicle N=9) reduced p-ERK-1/2 expression in the incised 
tissue and blocked hypersensitivity in MKP-3 KO mice (N=6). The findings of this study 
suggest that MKP-3 is pivotal for normal resolution of acute postoperative allodynia, through 
the regulation of peripheral p-ERK-1/2. 
Keywords: DUSP-6, p38, ERK  
Introduction
Although effective treatment can resolve acute postsurgical pain in many patients, 
30%–50% of individuals who undergo common invasive surgeries suffer persistent 
postoperative pain.1 The nociceptive processes under these conditions are not fully 
understood, and our knowledge on the triggers of persistent postsurgical pain is lim-
ited. Identifying these factors (ie, targets) will aid the development of more adequate 
non-invasive therapies.2 
Studies of pain axes in the spinal cord have shown that mitogen-activated protein 
kinases (MAPKs) contribute to the initiation and maintenance of post-surgical pain. 
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Inactivation of phosphorylated MAPK p38 (p-p38) success-
fully reduced pain-related behaviors in rodents, following 
plantar incision surgery3,4 and treated postoperative pain in 
humans.5 The role of MAPKs is also instrumental in chronic 
pain conditions. Phosphorylation of p38 or extracellular 
signal-regulated kinase (ERK)-1/2, another MAPK, is nec-
essary for the development and perpetuation of mechanical 
hypersensitivity, as observed in models of chronic neuro-
pathic6 and acute-to-chronic postoperative pain.3,7,8 Although 
p38 inhibition has demonstrated some efficacy in neuropathic 
pain in humans,9,10 its role in this condition remains unclear.11
Even though the pathophysiological events in the spinal 
cord are important for the maintenance of postoperative 
pain,3,7,8 cellular and molecular processes at the site of the 
surgical incision are also relevant. Studies on injured tissue in 
rodents, following paw incision, have linked the up-regulation 
of neurotrophin and cytokine genes with postoperative 
pain.12 Molecular mediators such as nerve growth factor,13 
lactic acid,14 prostaglandins,15 and complement factor,16 in 
the incised tissue are also related to postoperative pain. 
Moreover, inhibition of p-p38 and phosphorylated ERK-
1/2 (p-ERK-1/2), in the mouse peripheral tissue, reduced 
nociceptive behaviors in a model of phorbol 12-myristate 
13-acetate-induced inflammatory pain.17 Increased levels of 
a downstream MAPK signaling product, interleukin 6, at 
the incision site, are associated with postoperative pain in 
humans18 and with the development of hyperalgesia in murine 
pain models.19–21 This study proposes that a dysregulation of 
the peripheral mechanisms that promote MAPK deactivation 
underlies the transition from acute to persistent postopera-
tive pain.  
MAPK phosphatases (MKP) are the major negative 
regulators of MAPKs. Specifically, MKP-3 preferentially 
dephosphorylates p-ERK-1/2, whereas MKP-1 favors p-p38 
dephosphorylation.22,23 However, their substrate preference 
varies between cell types, anatomical locations, or patho-
logical conditions.7,24 It has been demonstrated that MKPs can 
act as potential analgesic targets.25,26 This study showed that 
impaired MKP-3 signaling in the spinal cord leads to persistent 
mechanical hypersensitivity, through dysregulation of p-p38 
and p-ERK-1/2.7 Moreover, it demonstrated that spinal induc-
tion of MKP-1 prevents neuropathic mechanical hypersensi-
tivity in rats.27 In addition to their role in the central nervous 
system, MKP-1 and MKP-3 mediate peripheral inflammatory 
 processes.28,29 However, the contribution of MKPs at the 
peripheral sites in pain conditions has not been investigated. 
This study aimed to understand the role of MKPs and 
their target MAPKs at the site of the surgical incision in 
nociceptive behavior in mice. Based on previous studies,7,26 
it is hypothesized that the dysregulation of peripheral MKP-3 
will result in persistent ERK-1/2 and p38 phosphorylation 




Wild-type (WT, B6129SF2/J) and MKP-3 knockout (KO, 
B6129X1-Dusp6 TM1Jmol/J) male and female (50–60 days 
old) mice were used (The Jackson Laboratory, Bar Harbor, 
ME, USA). MKP-3 KO mice were reported to be deficient 
in MKP-3 protein in the spleen, heart, lungs, and thymus 
tissues.30 It was shown that MKP-3 KO mice lack MKP-3 pro-
tein in the spinal cord.7 The authors confirmed that these mice 
also lack MKP-3 in the paw tissue (Figure 1). The animals 
were housed individually and maintained in light-dark cycles 
for 12 h with ad libitum access to food and water. All animal 
procedures were done in accordance with the Guidelines for 
Animal Experimentation of the International Association 
for the Study of Pain and were approved by the Institutional 
Animal Care and Use Committee at Dartmouth College. All 
the animals (KO or WT) used for behavioral experiments 
or that received treatment or that were used for tissue col-
lection and molecular assessments were distributed using a 
randomized allocation to different groups. The method used 
was simple, choosing random numbers that coincide with the 
identification number of the animals from a list including all 






































Figure 1 50% paw withdrawal threshold (A) in naïve mice and mice that underwent 
paw incision surgery, measured on days 1, 5, 7, and 12 in wild-type (WT, open 
circles [] n=6) and in MKP-3 KO mice (closed circles [•] n=6). Data were analyzed 
using two-way ANOVA + Bonferroni post hoc analysis. *P<0.05, WT vs MKP-3 KO. 
Representative Western blot images (B) of hind paw plantar tissue MKP-3 and MKP-
1 (β-actin was used as the loading control) in WT and MKP-3 KO naïve mice. Data 
are expressed as mean ± SEM.
Abbreviations: WT, wild type; KO, knockout; ANOVA, analysis of variance; 
MKP-3, Mitogen-activated protein kinase phosphatase-3; SEM, standard error of 
mean.
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Surgery: paw incision model of 
postoperative pain
All the animals were anesthetized with isoflurane (4% induc-
tion, 2% maintenance) in oxygen, delivered through a nose 
cone. Plantar aspect of the left hind paw was sterilized with 
providone-iodine before and after surgeries. Approximately 
0.5 cm longitudinal incision was made through skin and fas-
cia of the plantar aspect of the left hind paw from the heel to 
the base of the toes, using a No. 10 scalpel blade and sterile 
technique. The plantaris muscle and ligaments were elevated 
and stretched for 6–8 s (they were not incised). The wound 
was cleaned and apposed with inverted 6.0 silk sutures (Ethi-
con Inc., Somerville, NJ, USA). The animals were allowed 
to recover from the surgery for 1 h and maintained with ad 
libitum access to food and water.31,32
Behavioral testing
Mechanical allodynia, measured as 50% withdrawal thresh-
old, was assessed in the ipsilateral paw to surgery using von 
Frey filaments (0.07-, 0.17-, 0.40-, 0.60-, 1.04-, 1.37-, and 
2.0-g bending force) (Stoeling, Wood Dale, IL, USA) and 
calculated using an up-down statistical method.3,33 In both 
WT and KO animal groups, baseline behavior was tested in 
naïve mice (no surgery), as well as 1, 5, 7, and 12 days after 
surgery (n=6 per group; 6 males in each group). The animals 
were followed up until postoperative day 12 since it had been 
previously shown that paw incision-induced inflammation, 
measured as paw circumference, returns to baseline levels on 
day 12 after surgery.7 An additional group of MKP-3 KO mice 
(n=3) was used to assess the role of MAPKs; 50% withdrawal 
threshold was measured before the surgery, 12 days after 
surgery, and 0.5, 1, and 2 h after intraplantar injection of an 
MEK inhibitor (PD98059) that blocks phosphorylation of 
ERK-1/2, administered on day 12. Two experimenters (blind 
to treatment conditions) performed two sets of experiments; 
the data were combined for analysis. 
Cellular infiltration
Animals were anesthetized and perfused transcardially 
using 0.1 M phosphate-buffered saline, followed by 4% 
formaldehyde. Tissue from the operated paw was removed 
in a consistent manner: the center of the incision wound 
was localized, and a No. 10 blade was used to cut the soft 
tissue 1.5 mm apart from the center, rostrally, and caudally. 
The plantar bones determined the depth of the collected 
tissue; the tissue was removed from the paw by an addi-
tional longitudinal cut above the bone of the paw. A 3 mm 
piece of plantar paw tissue was placed in 30% sucrose 
solution for 48–72 h, at 4ºC. The tissue was mounted and 
frozen in optimal cutting temperature compound (Sakura 
Finetek, Torrence, CA, USA) at −80ºC. Hematoxylin and 
Eosin (H&E) staining was performed on 20 μm paw tissue 
sections, cut using Leica CM1859 Cryostat, according to 
standard protocols. The stained tissues were dehydrated and 
sealed with Vectashield mounting medium (Vector Labs, 
Burlingame, CA, USA). Images were obtained using Q-fired 
cooled CCD camera attached to an Olympus microscope 
BX60. H&E staining was performed on two groups of ani-
mals (n=3 male animals per group, WT and MKP-3 KO), 
prior to (naïve) and on different days after surgery (days 
1, 5, 7, and 12). Three tissue sections per animal per time 
point were evaluated for the number of infiltrating cells. 
Three areas of 0.1 mm2 per tissue section were scored and 
averaged. The percentage of polymorphonuclear (PMN) 
and mononuclear cells was assessed morphologically. One 
experimenter (blind to genotype conditions) performed 
this analysis.
Drugs and intraplantar injections
PD98059, an MEK inhibitor used to block p-ERK-1/2 
expression (Sigma-Aldrich Co., St. Louis, MO), was diluted 
in dimethylsulfoxide and saline (1:1, vehicle). PD98059 
(25 nmol, 8 μL), or vehicle, was injected intraplantary to the 
left hind paw of MKP-3 KO mice (ipsilateral to surgery), on 
postoperative day 12. The concentration of the drug was chosen 
based on a previous study7 and other pain mouse models.34 
Mechanical allodynia was assessed before surgery and on 
postoperative day 12, prior to PD98059 injection, as well as 
0.5, 1, and 2 h following drug administration. The experimenter 
performed these studies blind to treatment conditions (n=9, six 
males and three females in the vehicle treated group; n=8, five 
males and three females in the MEK inhibitor-treated group). 
Western blot was performed on six paw tissue samples, five 
male mice and one female mouse, from each treatment group. 
Western blot 
The animals were euthanized using decapitation under iso-
flurane anesthesia (4% in oxygen). The plantar tissues of the 
left hind paw (ipsilateral) were removed using the method 
described in the “Cellular Infiltration” section. A 3 mm piece 
of tissue was obtained and processed; tissue was sonicated in 
PBS, with 1:1000 protease inhibitors (Sigma-Aldrich Co.). 
Protein concentrations were determined by DC assay (Bio-
Rad Laboratories Inc., Hercules, CA, USA). A 50 μg protein 





sample was loaded onto sodium dodecyl sulfate (SDS) poly-
acrylamide electrophoresis gel (10%; Bio-Rad Laboratories 
Inc.). The protein was transferred to a 0.2 μm nitrocellulose 
membrane (Bio-Rad Laboratories Inc.) and processed as pre-
viously described.7 Primary antibodies used were as follows: 
mouse anti-p-ERK-1/2 (1:1000), rabbit anti-p-p38 (1:1000), 
mouse anti-ERK-1/2 (1:1000), rabbit anti-p38 (1:500) (Cell 
Signaling Technology, Inc., Danvers, MA, USA), rabbit 
anti-MKP-1 (1:500; Santa Cruz Biotechnology Inc., Dallas, 
TX, USA), and rabbit anti-MKP-3 (1:3000; Cell Signaling 
Technology). β-Actin was used as loading control and stained 
using mouse anti-β-actin primary antibody (1:3000; Abcam, 
Cambridge, MA, USA). Following primary antibody incuba-
tion (16–20 h at 4°C), the blots were washed in tris-buffered 
saline (TBS) + 0.05% Tween 20 and incubated for 1 h at room 
temperature in one of the following secondary antibodies: 
goat anti-mouse HRP-conjugated antibody (1:3000; Bethyl 
Laboratories Inc., TX, USA) or goat anti-rabbit horseradish 
peroxidase (HRP)-conjugated antibody (1:3000; Pierce, 
Rockford, IL, USA). Subsequently, the blots were washed 
and visualized using Super Signal West Femto Maximum 
Sensitivity Substrate (Pierce). Imaging was conducted using 
Syngene G-Box system and software (Synoptics, Frederick, 
MD, USA). Following visualization, the membranes were 
incubated for 25 min at 37°C in 5% sodium azide TBS buffer 
and re-probed with another primary and secondary antibody 
as described previously.7 In some cases (MKP-3 and MKP-1 
Western blots), β-actin blots were run simultaneously on a 
different membrane using the same samples and same protein 
amounts in both membranes.  
Signal intensity of the protein of interest was assessed 
using Image J software, and the data were quantified by divid-
ing the intensity of the signal of the protein of interest with 
the corresponding signal intensity of β-actin. Quantifications 
of p-ERK-1/2 and p-p38 levels were done by normalizing 
p-ERK-1/2, ERK-1/2, p-p38, and p38 against β-actin, after 
which p-ERK-1/2 and p-p38 data were quantified as relative 
intensity of the particular signal, divided by the previously 
normalized value of total ERK-1/2 and total p38, respectively. 
For the MKP-1, MKP-3, p-ERK, and p-p38 time course 
quantification studies in WT and MKP-3 KO groups, two 
independent experimenters (blind to genotype conditions) 
performed these analyses, and both the sets of data were 
combined (n=3 male mice per group). 
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 
(GraphPad Software Inc., La Jolla, CA, USA), and all data 
are expressed as mean ± standard error of mean (SEM). The 
size of the samples was decided based on previous publica-
tions by these authors, and therefore, no a priori statistical 
power calculation was conducted.7,24 Normality was tested 
using Shapiro–Wilk test. Two data sets from the MEK 
inhibitor (PD98059) group and one data set from the vehicle 
group were identified as outliers (2-fold standard deviation) 
and therefore excluded from the analysis in the behavioral 
experiments.
Behavior data were analyzed using a repetitive mea-
surement two-way analysis of variance (ANOVA) followed 
by Bonferroni post hoc test; N=6. The values for cellular 
infiltration measurements after the paw incision did not 
follow a normal distribution and were analyzed as non-
parametrical data. Kruskal–Wallis followed by a Dunn test 
was performed to determine the changes in cellular infiltra-
tion against the baseline values (naïve mice) in each group. 
Mann–Whitney U test was performed to compare the effects 
on cellular infiltration between the KO and WT groups at 
each time point; N=6. The Western blot analyses between 
groups were determined by one-way ANOVA followed by 
Dunnett’s post-test using the naïve group as the control, 
or two-way ANOVA followed by Bonferroni’s post-test, as 
appropriate, N=3. Comparison of the relative expression 
of p-ERK-1/2 in PD98059-treated versus vehicle-treated 
group in KO mice was performed using Mann–Whitney U 
test for non-parametrical data (N=6). A P-value <0.05 was 
considered statistically significant. 
Results
Relationship between MKP-3 and pain-
related behaviors in the mouse model of 
acute postoperative pain
In both WT and MKP-3 KO mice, paw incision surgery led to 
an equal level of mechanical hypersensitivity on postopera-
tive day 1 (Figure 1A). Although the 50% withdrawal thresh-
old in WT mice returned to baseline levels on postoperative 
day 12, mechanical allodynia in MKP-3 KO mice continued 
until 7–12 days after surgery (Figure 1A). 
As previously demonstrated, MKP-3 KO mice did not 
exhibit overtly altered behavior when compared with WT 
mice.7 Development and grooming were comparable between 
the two murine strains. It was confirmed that MKP-3 KO 
mice did not express MKP-3 protein in the paw tissue and 
that MKP-1 protein expression was consistent between WT 
and MKP-3 KO mice (Figure 1B), thus excluding potential 
compensatory mechanisms. 
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Role of peripheral inflammation in 
mechanical allodynia in WT and MKP-3 
KO mice
This study evaluated the cellular infiltration levels in the paw 
tissue 1–7 days after surgery and compared it with cellular-
ity at baseline and at day 12 after surgery. H&E histological 
staining in WT mice showed a significant increase in the 
number of infiltrating cells on postoperative day 5 after 
surgery, which remained elevated at day 7 after surgery 
(Figure 2A and B). In contrast, in MKP-3 KO mice, the 
number of infiltrating cells significantly increased on 
postoperative day 1, in which a peak effect and a signifi-
cant difference compared to the WT group was observed. 
The number of cells in the KO mice declined initially but 
remained significantly elevated on postoperative days 5 and 7 
(Figure 2A and B). However, these values were not different 
from the WT group values (Figure 2A and B). The degree 
of cellular infiltration returned to basal levels 12 days after 
surgery in both the groups. 
When different populations of PMN and mononuclear 
cells were evaluated, it was found that the percentage of 
PMN cells in the MKP-3 KO mice (86.9±2.8%) was sig-
nificantly higher than that in WT mice (77.1±5.1%) 1 day 
after surgery (P=0.02). A decrease in the percentage of PMN 
cells was found at the later points after paw incision in both 
MKP-3 KO and WT mice, but no changes in the percent 
of PMN cells were found between the groups on postop-
erative days 5 (MKP-3 KO =31.4±5.7%, WT =22.9±3.3% 
PMN cells, P=0.20) and 7 (MKP-3 KO =18.5±5.2%, WT 
=13.1±2.3% PMN cells, P=0.10). The proportion of mono-
nuclear cells was smaller than the proportion of PMN cells 
on postoperative day 1 in both MKP-3 KO and WT mice, 
as expected. However, a lower percentage of mononuclear 
cells was obseverd on postoperative day 1 in the MKP-3 KO 
group (13.1±4.0%) compared to the WT group (22.9±5.1%, 
P=0.02). Conversely, a predominant proportion of mono-
nuclear cells was observed on postoperative days 5 (MKP-3 
KO =68.6±5.73%, WT =77.1±4.6% PMN cells, P=0.14) 
and 7 (MKP-3 KO =81.5±5.2%, WT =86.9±2.28% PMN 
cells, P=0.10) in both MKP-3 KO and WT groups, but no 
significant differences were found between these groups.
p-ERK-1/2 and p-p38 expression levels 
in the paw tissue of WT and MKP-3 
KO mice
Since MAPKs are the natural substrates of MKP-3, and 
MAPKs determine at least in part the pro-inflammatory phe-
notype of immune cells, the phosphorylation level of p-ERK 
and p-p38 was studied in the paw soft tissue (surgical area). 
In WT mice, levels of p-ERK-1/2 protein were significantly 
elevated on postoperative days 1 and 5, and no significant 
differences were observed between day 7 or 12 after sur-
gery and the naïve animals (Figure 3A and B). Similarly, 
expression levels of p-p38 protein significantly increased on 
postoperative days 1–5, and no statistical differences were 
observed between day 7 or 12 after surgery and the naïve 
groups (Figure 3A and C). These observations are consistent 
with the decrease in paw edema7 and cellular infiltrates, as 
well as with the resolution of mechanical allodynia in WT 
mice, on days 7–12 following surgery. 
In MKP-3 KO mice, p-ERK-1/2 protein levels were 
significantly elevated on postoperative day 1 and remained 
consistently elevated all through postoperative day 12, rela-
tive to the protein levels in naïve MKP-3 KO mice (Figure 3A 
and D). On the contrary, p-p38 expression patterns in MKP-3 
KO mice after paw incision surgery resembled those of WT 
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Figure 2 Representative images of H&E staining (A) (scale bar =100 µm) of paw 
tissue ipsilateral to incision of wild-type (WT) and MKP-3 KO mice, in naïve mice 
(left hind paw plantar tissue) and on days 1, 5, 7, and 12 after paw incision surgery. 
Cellular and nuclear morphology of some cells are shown in magnified inserted 
images (scale bar =20 µm). Quantification of the number of infiltrated cells (B) in 
paw tissue ipsilateral to incision of wild-type (WT) and MKP-3 KO mice, in naïve 
mice (left hind paw plantar tissue) and on days 1, 5, 7, and 12 after paw incision 
surgery (n=3/group). The number of polymorphonuclear cells (line pattern) and 
mononuclear cells (solid color) is represented within each bar. *P<0.05 vs naïve, 
Kruskal–Wallis tests followed by a Dunn test; #P<0.05 WT vs MKP-3 KO, Mann–
Whitney U test. Data are expressed as mean ± SEM.
Abbreviations: H&E, hematoxylin and eosin; WT, wild type; KO, knockout; MKP-
3, Mitogen-activated protein kinase phosphatase-3; PMN, polymorphonuclear cells; 
SEM, standard error of mean.





1–7; they subsided by day 12 after surgery, relative to naïve 
mice (Figure 3A and E). 
MKP-3 and MKP-1 expression levels 
in the paw tissue of WT and MKP-3 
KO mice
In order to understand the temporal MAPK dynamics observed 
in the soft tissue of the operated paw, temporal expression of 
MKP-3 in WT mice and the expression of MKP-1, the other 
major regulator of MAPKs, were studied. In WT mice, MKP-3 
expression levels in the paw tissue increased on postoperative 
days 5–7 (Figure 4A and C), in accordance with the declin-
ing expression levels of p-ERK-1/2 and p-p38 at these time 
intervals (Figure 3). Although MKP-1 expression in the WT 
paw tissue initially declined on postoperative day 1, MKP-1 
protein levels increased 7 days after surgery (Figure 4A and 
D), potentially contributing to the return of p-p38 and p-ERK-
1/2 expression to basal levels on postoperative day 12. 
In MKP-3 KO mice, MKP-1 expression levels in the 
paw tissue increased on postoperative day 1, but returned to 
baseline levels on days 5–12 after surgery, relative to naïve 
mice (Figure 4B and D). The difference in MKP-1 expression 
levels between WT and MKP-3 KO mice, on postopera-
tive day 1, could be due to a compensatory mechanism in 
MKP-3 KO mice following paw incision. Interestingly, the 
high expression of p-p38 on postoperative day 1 is not in 
Days after surgery
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Figure 3 Representative Western blot images of p-ERK-1/2, total-ERK-1/2, p-p38, total-p38 and β-actin (loading control) from paw tissue of wild-type and MKP-3 KO mice, 
in naïve condition and on days 1, 5, 7, and 12 after paw incision surgery (A). Quantification of p-ERK-1/2 (B) and p-p38 (C) expression in the paw tissue of wild-type mice, 
and p-ERK-1/2 (D) and p-p38 (E) expression in the paw tissue of MKP-3 KO mice, in naïve condition and on days 1, 5, 7, and 12 after paw incision surgery (n=3/group). Data 
were normalized to naïve condition and analyzed using one-way ANOVA + Dunnett’s post-test, *P<0.05 vs naïve. Data are expressed as mean ± SEM.
Abbreviations: ERK, extracellular signal-regulated kinase; KO, knockout; MKP-3, Mitogen-activated protein kinase phosphatase-3; ANOVA, analysis of variance; SEM, 
standard error of mean.
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accordance with the elevation of MKP-1 protein levels in 
MKP-3 KO mice, despite p-p38 being the primary MKP-1 
substrate. This suggests that other factors might contribute 
to the regulation of p-p38 at the early stages after surgery, 
for example, MKP-3.
Effects of inhibiting ERK-1/2 
phosphorylation in the paw tissue of 
MKP-3 KO mice
This study observed that p-ERK-1/2 expression levels 
remained elevated in the paw tissue of MKP-3 KO mice 
on postoperative day 12, contrary to the unchanged p-p38 
levels, relative to naïve mice (Figure 3D and E). To test a 
potential causative association between persistent p-ERK 
and persistent allodynia, the effect of inhibiting MEK was 
studied, which subsequently prevents ERK phosphorylation, 
in the paw tissue, on mechanical allodynia in MKP-3 KO 
mice, 12 days after surgery.
It was also observed that local intradermal administration 
of a small molecule MEK inhibitor, PD98059 (25 nmol), par-
tially, but significantly, reversed incision-induced persistent 
mechanical allodynia 1–2 h after injection, compared to the 
vehicle-treated group (Figure 5A). To confirm the inhibitory 
effects of PD98059 over p-ERK-1/2, its expression levels 
after treatment were measured. A partial but significant 
reduction in p-ERK-1/2 expression was observed in the paw 
tissue 2 h after treatment, compared to the vehicle (Figure 5B 
and C). These data strongly suggest a causative relation-
ship between peripheral p-ERK expression and persistent 
postoperative hypersensitivity observed in MKP-3 KO mice.
Discussion
This study demonstrates that lack of MKP-3 protein in mice 
leads to a long-lasting phosphorylation of MAPK ERK-1/2 
in the peripheral tissue following a surgical intervention 
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Figure 4 Representative Western blot images of MKP-1, MKP-3, and β-actin (loading control) from paw tissue of WT mice (A), in naïve condition and on days 1, 5, 7, and 
12 after paw incision surgery, and representative Western blot images of MKP-1 and β-actin (loading control) from paw tissue of MKP-3 KO mice (B), in naïve condition 
and on days 1, 5, 7, and 12 after paw incision surgery. Quantification of MKP-3 expression in the paw tissue of WT (C) and of MKP-1 expression in the paw tissue of MKP-3 
KO mice (D), in naïve condition and on days 1, 5, 7, and 12 after paw incision surgery (n=3/group). Data were analyzed using one-way ANOVA + Dunnett’s post-test (C) or 
two-way ANOVA + Bonferroni post hoc (D); *P<0.05 vs naïve. Data are expressed as mean ± SEM.
Abbreviations: WT, wild type; KO, knockout; MKP-3, mitogen-activated protein kinase phosphatase-3; ANOVA, analysis of variance; SEM, standard error of mean.





 mechanical allodynia. The major novelty of this study is 
therefore the discovery of the important role that MKP-3 
plays in the periphery in the transition from acute to chronic 
postoperative mechanical hypersensitivity. 
It has been previously shown that dysregulation of MKPs 
in the spinal cord is associated with chronic neuropathic 
pain, such that MKP-1 and MKP-3 induction in the spinal 
cord reduced mechanical allodynia in the rat model of neu-
ropathic pain.26,27 In a more recent study, a mouse model 
of acute postoperative pain was used, that is, paw incision 
surgery, to demonstrate that MKP-3 also plays a role in the 
transition from acute to chronic postoperative mechanical 
allodynia through mechanisms in the spinal cord.7 Using 
the same model, this study aimed to understand the role of 
MKP-3 in the mechanisms governing persistent mechanical 
hypersensitivity in the peripheral tissue, as a more clinically 
relevant, accessible, and feasible treatment site. 
This study confirms that lack of MKP-3 does not alter 
nociceptive behaviors in mice in response to mechanical 
stimulation under normal conditions. Moreover, the absence 
of MKP-3 does not influence the extent of acute mechanical 
allodynia (postoperative day 1). Nonetheless, lack of MKP-3 
influences the transition from acute to chronic postoperative 
hypersensitivity. These data indicate that the function of 
MKP-3 in the peripheral injured tissue is minimal in nocicep-
tive basal tone and the early stages of postoperative hypersen-
sitivity. However, under normal conditions, peripheral MKP-3 
seems to play a key role in the resolution phase of postsurgical 
mechanical allodynia by dephosphorylating p-ERK. This is 
supported by the temporal pattern of expression of peripheral 
MKP-3 and p-ERK following paw incision in WT animals. 
For example, expression levels of paw p-ERK decline as 
postoperative allodynia resolves in WT mice (postoperative 
days 7–12). This temporal pattern correlates well with the 
expression of MKP-3 in the injured tissue in these mice, which 
increases on postoperative days 5–7 and returns to baseline on 
day 12. This assumption is confirmed by the fact that the lack 
of MKP-3 (KO mice) results in a persistent p-ERK expres-
sion in the injured tissue. These findings show that MKP-3 
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Figure 5 50% paw withdrawal threshold (A) in MKP-3 KO mice before (baseline, BL) and 12 days following paw incision (D12), and 0.5, 1, and 2 h following intraplantar 
administration of 25 nmol PD98059 (MEK-1/2 inhibitor, n=8) or vehicle (n=9) on postoperative day 12. Data were analyzed using two-way ANOVA + Bonferroni’s post 
hoc analysis. *P<0.05 vs vehicle. Representative Western blot images of p-ERK-1/2, total-ERK-1/2, and β-actin (loading control) (B) from paw tissue of MKP-3 KO mice 
(postoperative day 12) 2 h following intraplantar administration of PD98059 or vehicle. Quantification of p-ERK-1/2 expression (C) in paw tissue of MKP-3 KO mice 
(postoperative day 12) 2 h following intraplantar administration of PD98059 or vehicle (n=6 per group, five male mice and one female mouse, from each treatment group). 
Data were analyzed using one-way ANOVA + Bonferroni’s post hoc analysis. *P<0.05 versus vehicle. Data are expressed as mean ± SEM.
Abbreviations: WT, wild type; KO, knockout; ERK, extracellular signal-regulated kinase; MKP-3, mitogen-activated protein kinase phosphatase-3; ANOVA, analysis of 
variance; SEM, standard error of mean.
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thus promotes the resolution of postoperative hypersensitivity 
in acute postoperative pain. 
The current study also uncovers a differential substrate 
preference of MKP-3 between the periphery and the spinal 
cord in mice. Even though MKP-3 can modulate different 
MAPKs, MKP-3 preferentially dephosphorylates p-ERK 
in most systems.22,23 It has been previously demonstrated 
that MKP-3 in the spinal cord modulates both p-ERK and 
p-p38 to a similar extent,7 and furthermore that MKP-3 
preferentially dephosphorylates m-JNK (another major 
MAPK) in the rat brain-derived astrocytes.24 Together, 
these data strongly suggest that the substrate preference of 
MKP-3 is determined by the relevance of a given MAPK 
in a given tissue. This is consistent, for example, with the 
prominent role of p-JNK in astrocytic function.35,36 Herein, 
this study observed that the temporal pattern of expression 
of peripheral p-p38 following paw incision was not altered 
in MKP-3 KO mice when compared to WT mice. In other 
words, p-p38 is dephosphorylated at the time of resolution 
of postoperative allodynia even in the absence of MKP-3. 
Therefore, the current results demonstrate that MKP-3 pre-
serves its selectivity for p-ERK at the periphery, since the 
lack of MKP-3 (KO mice) resulted in persistent expression 
of p-ERK that paralleled the persistent mechanical hyper-
sensitivity in these mice. This study confirms the functional 
association between the lack of MKP-3, persistent p-ERK 
expression in the peripheral injured tissue, and the mainte-
nance of postoperative mechanical hypersensitivity using 
an MEK inhibitor. Accordingly, phosphorylation of ERK in 
the peripheral tissues during inflammation contributes to the 
pain-related behaviors in several rodent models.37–39 Since 
the findings indicate that persistent p-ERK expression on 
postoperative day 12 is not associated with cell infiltration 
(resolved at this time point), these data suggest that this 
MAPK phosphorylation takes place in non-immune cells, 
namely nerve fibers or skin cells. It has been demonstrated 
that an elevation of p-ERK expression in epidermal and 
dermal peripheral nociceptors (C-fibers) is responsible for 
capsaicin-induced thermal and mechanical hypersensitiv-
ity.40,41 An increase in p-ERK-1/2 and p-p38 expression 
as well as a functional association between the two have 
been observed in keratinocytes of psoriatic lesions in 
humans42–44 and in mouse keratinocytes under pruritogenic 
conditions.45 Furthermore, p-ERK expression is enhanced 
in human keratinocytes in in vitro models of acute and 
chronic wounds.46,47 The phosphorylation of ERK can also 
be induced by pro-algesic factors such as epidermal growth 
factor.47 Since ERK phosphorylation induces the production 
of pro-algesic factors by non-neuronal cells that sensitize 
peripheral nociceptors, which in turn are characterized by 
neuronal ERK phosphorylation,6 it is likely that the results 
are explained by a pronociceptive feedback loop of skin cell 
and peripheral nociceptor ERK phosphorylation.   
The findings of this study indicate that, although some 
aspects of the neuroinflammatory process might resolve in 
a timely fashion, following a peripheral insult, they might 
not be indicative of a complete resolution of the peripheral 
mechanisms underlying the transition from acute to chronic 
pain. It is plausible that the magnitude of the early cellular 
infiltration contributes to the persistent elevation of p-ERK 
in the periphery (nociceptors and/or skin cells) and subse-
quently to the transition from acute to chronic pain in MKP-3 
KO mice. Immunohistochemistry staining to determine the 
specific repertoire of immune cells might better elucidate the 
role of immune cell infiltration in the resolution of postop-
erative pain. Whether the MAPK/MKP signaling pathway 
pattern could be used as a biomarker to identify potential 
patients at risk of developing chronic postoperative pain, or 
those already suffering from it, remains to be studied. It is 
certainly a testable hypothesis (minimal required invasiveness 
for assessment) that deserves further study. These studies in 
human tissue would move forward the field to set a rationale 
for potential studies with already available p-ERK inhibitors 
(some already evaluated in clinical trials for osteoarthritis 
or cancer).48,49 
This study also suggests that p-ERK, even though it pro-
motes a cellular pro-inflammatory phenotype, does not seem 
to play a role in cellular infiltration. On the other hand, p-p38 
seems to be functionally associated with the initiation and 
resolution of cell infiltration, because of the similar pattern 
of appearance of these phenomena in both WT and MKP-3 
KO groups. These hypotheses are in line with previous 
observations, in which the intraarticular inhibition of p-p38 
or p-JNK, but not p-ERK, reduced cellular infiltration into 
the synovium, in a carrageenan-induced arthritis rat model.50 
Therefore, this study does not rule out the potential role of 
peripheral p-p38 in the transition from acute to chronic pain. 
Similarly, the role of MKP-1 (which preferentially dephos-
phorylates p-p38) in the peripheral mechanisms of chronic 
pain cannot be ruled out. Elevated MKP-1 expression in 
MKP-3 KO mice on postoperative day 1 could suggest a 
compensatory mechanism triggered by surgical incision 
and the initial events of postoperative hypersensitivity. The 
high levels of p-p38 expression in the presence of elevated 





MKP-1expression in the early stages of acute postoperative 
pain in MKP-3 KO animals suggest that other factors, besides 
MKP-1, might be involved in p38 regulation. Based on the 
observation that p-p38 dephosphorylation associates with the 
resolution of inflammation, it is speculated that inflammatory 
mediators could be involved in p38 modulation.
The role of MAPKs, such as p-ERK, in chronic pain 
models is well recognized.6,51 Activation of MAPKs is 
required for effective production of pro-algesic factors that 
sensitize peripheral nociceptors and subsequently perpetu-
ate MAPK phosphorylation, leading to central sensitization 
and establishment of chronic pain.27 The induction of an 
effective MKP activity could break this cycle and interrupt 
the molecular signals driving the transition to chronic pain. 
It has been demonstrated that novel approaches could be 
utilized to develop gene therapies, for example, induction 
of MKP expression to modulate cell phenotype and treat 
chronic pain.27 The induction of MKPs can also be achieved 
by pharmacological approaches. For example, glucocorti-
coids52 or cannabinoids26 produce anti-inflammatory effects 
by inducing MKP-1 and/or MKP-3. Curiously, the use of 
glucocorticoids in surgical patients seems to reduce the use 
of analgesics in postoperative pain.53,54 
Although this study focused on peripheral MKP-3 and 
MAPK molecular changes in the context of postoperative 
pain resolution, it recognizes that multiple factors, such as 
genetics,55,56 preoperative pain and physiological states,57 
psychological vulnerability,58 and surgical techniques,59 con-
tribute to post-surgical pain and its persistence. It warrants 
further investigation on the potential association of these 
factors with the abovementioned pathways. 
Conclusion
This study revealed that MKP-3/p-ERK-1/2 signaling in 
the periphery greatly influences the transition from acute 
to chronic postoperative pain. The current data further sup-
port the notion that biochemical and regulatory properties 
of MKP-3 render it a promising target for preventing and 
treating chronic postoperative pain. Moreover, studies by 
the authors uncover the possibility of intervening at the site 
of surgery, which provides a more feasible therapeutic site 
than the central nervous system.60 
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